Vascular pathology in multiple sclerosis: Mind boosting or myth busting?

Experimental and Translational Stroke Medicine

Volumn 3, Issue 1, 2011, Pages

  Waschbisch, Anne ^a   Manzel, Arndt ^a   Linker, Ralf A ^a   Lee, De Hyung ^a  

^a Department of Neurology ^*  (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN CONVERTING ENZYME 2; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANGIOGRAPHY; AUTOIMMUNE DISEASE; BALLOON DILATATION; BLOOD BRAIN BARRIER; BRAIN VEIN; CENTRAL NERVOUS SYSTEM INFECTION; CHRONIC CEREBROSPINAL VENOUS INSUFFICIENCY; DEMYELINATING DISEASE; DIFFUSION WEIGHTED IMAGING; DISEASE MARKER; DOPPLER ECHOGRAPHY; ENCEPHALOMYELITIS; ERYTHROCYTE; HUMAN; IMMUNOMODULATION; INTERNAL JUGULAR VEIN; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE; PARTICIPANT OBSERVATION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PHLEBOGRAPHY; PREVALENCE; PRIORITY JOURNAL; RECURRENT DISEASE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIDEROSIS; STENOSIS; SUBARACHNOID HEMORRHAGE; VASCULAR DISEASE; VEIN BLOOD FLOW; VENOUS PRESSURE;

EID: 80051660869     PISSN: None     EISSN: 20407378     Source Type: Journal    
DOI: 10.1186/2040-7378-3-7     Document Type: Review

References (87)

1. Zamboni P, Galeotti R, Menegatti E, Malagoni AM, Tacconi G, Dall'Ara S, Bartolomei I, Salvi F. Chronic cerebrospinal venous insufficiency in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 2009, 80:392-399. 2647682, 19060024.
2. Hojnacki D, Zamboni P, Lopez-Soriano A, Galleotti R, Menegatti E, Weinstock-Guttman B, Schirda C, Magnano C, Malagoni AM, Kennedy C, Bartolomei I, Salvi F, Zivadinov R. Use of neck magnetic resonance venography, Doppler sonography and selective venography for diagnosis of chronic cerebrospinal venous insufficiency: a pilot study in multiple sclerosis patients and healthy controls. Int Angiol 2010, 29:127-139.
3. Zamboni P, Galeotti R, Menegatti E, Malagoni AM, Gianesini S, Bartolomei I, Mascoli F, Salvi F. A prospective open-label study of endovascular treatment of chronic cerebrospinal venous insufficiency. J Vasc Surg 2009, 50:1348-1358. 10.1016/j.jvs.2009.07.096, 19958985.
4. Zamboni P, Galeotti R. The chronic cerebrospinal venous insufficiency syndrome. Phlebology 2010, 25:269-279. 10.1258/phleb.2010.009083, 21106999.
5. Zamboni P, Menegatti E, Bartolomei I, Galeotti R, Malagoni AM, Tacconi G, Salvi F. Intracranial venous haemodynamics in multiple sclerosis. Curr Neurovasc Res 2007, 4:252-258. 10.2174/156720207782446298, 18045150.
6. Zamboni P, Menegatti E, Galeotti R, Malagoni AM, Tacconi G, Dall'Ara S, Bartolomei I, Salvi F. The value of cerebral Doppler venous haemodynamics in the assessment of multiple sclerosis. J Neurol Sci 2009, 282:21-27. 10.1016/j.jns.2008.11.027, 19144359.
7. Putnam TJ. Lesions of 'encephalomyelitis' and multiple sclerosis. Venous thrombosis as the primary alteration. JAMA 1937, 1477.
8. Singh AV, Zamboni P. Anomalous venous blood flow and iron deposition in multiple sclerosis. J Cereb Blood Flow Metab 2009, 29:1867-1878. 10.1038/jcbfm.2009.180, 19724286.
9. Zamboni P. The big idea: iron-dependent inflammation in venous disease and proposed parallels in multiple sclerosis. J R Soc Med 2006, 99:589-593. 10.1258/jrsm.99.11.589, 1633548, 17082306.
10. Simka M, Kostecki J, Zaniewski M, Majewski E, Hartel M. Extracranial Doppler sonographic criteria of chronic cerebrospinal venous insufficiency in the patients with multiple sclerosis. Int Angiol 2010, 29:109-114.
11. Al-Omari MH, Rousan LA. Internal jugular vein morphology and hemodynamics in patients with multiple sclerosis. Int Angiol 2010, 29:115-120.
12. Baracchini C, Perini P, Calabrese M, Causin F, Rinaldi F, Gallo P. No evidence of chronic cerebrospinal venous insufficiency at multiple sclerosis onset. Ann Neurol 2011, 69:90-99. 10.1002/ana.22228, 21280079.
13. Doepp F, Paul F, Valdueza JM, Schmierer K, Schreiber SJ. No cerebrocervical venous congestion in patients with multiple sclerosis. Ann Neurol 2010, 68:173-183.
14. Mayer CA, Pfeilschifter W, Lorenz MW, Nedelmann M, Bechmann I, Steinmetz H, Ziemann U. The perfect crime? CCSVI not leaving a trace in MS. J Neurol Neurosurg Psychiatry 2011, 82:436-440. 10.1136/jnnp.2010.231613, 3061048, 21296899.
15. Zivadinov R, Marr K, Cutter G, Ramanathan M, Benedict RH, Kennedy C, Elfadil M, Yeh AE, Reuther J, Brooks C, Hunt K, Andrews M, Carl E, Dwyer MG, Hojnacki D, Weinstock-Guttman B. Prevalence, sensitivity, and specificity of chronic cerebrospinal venous insufficiency in MS. Neurology 2011,
16. Meyer-Schwickerath R, Haug C, Hacker A, Fink F, Seidel D, Hartung HP, Haupts MR. Intracranial venous pressure is normal in patients with multiple sclerosis. Mult Scler 2011,
17. Worthington V, Killestein J, Eikelenboom MJ, Teunissen CE, Barkhof F, Polman CH, Uitdehaag BM, Petzold A. Normal CSF ferritin levels in MS suggest against etiologic role of chronic venous insufficiency. Neurology 2010, 75:1617-1622. 10.1212/WNL.0b013e3181fb449e, 20881272.
18. Sundstrom P, Wahlin A, Ambarki K, Birgander R, Eklund A, Malm J. Venous and cerebrospinal fluid flow in multiple sclerosis: a case-control study. Ann Neurol 2010, 68:255-259. 10.1002/ana.22132, 20695018.
19. Wattjes MP, van Oosten BW, de Graaf WL, Seewann A, Bot JC, van den BR, Uitdehaag BM, Polman CH, Barkhof F. No association of abnormal cranial venous drainage with multiple sclerosis: a magnetic resonance venography and flow-quantification study. J Neurol Neurosurg Psychiatry 2011, 82:429-435. 10.1136/jnnp.2010.223479, 20980483.
20. Zivadinov R, Galeotti R, Hojnacki D, Menegatti E, Dwyer MG, Schirda C, Malagoni AM, Marr K, Kennedy C, Bartolomei I, Magnano C, Salvi F, Weinstock-Guttman B, Zamboni P. Value of MR Venography for Detection of Internal Jugular Vein Anomalies in Multiple Sclerosis: A Pilot Longitudinal Study. AJNR 2011,
21. Zivadinov R, Lopez-Soriano A, Weinstock-Guttman B, Schirda CV, Magnano CR, Dolic K, Kennedy CL, Brooks CL, Reuther JA, Hunt K, Andrews M, Dwyer MG, Hojnacki DW. Use of MR venography for characterization of the extracranial venous system in patients with multiple sclerosis and healthy control subjects. Radiology 2011, 258:562-570. 10.1148/radiol.10101387, 21177394.
22. Yamout B, Herlopian A, Issa Z, Habib RH, Fawaz A, Salame J, Wadih A, Awdeh H, Muallem N, Raad R, Al-Kutoubi A. Extracranial venous stenosis is an unlikely cause of multiple sclerosis. Mult Scler 2010, 16:1341-1348. 10.1177/1352458510385268, 21041329.
23. Ludyga T, Kazibudzki M, Simka M, Hartel M, Swierad M, Piegza J, Latacz P, Sedlak L, Tochowicz M. Endovascular treatment for chronic cerebrospinal venous insufficiency: is the procedure safe?. Phlebology 2010, 25:286-295. 10.1258/phleb.2010.010053, 21107001.
24. Samson K. Experimental multiple sclerosis vascular shunting procedure halted at Stanford. Ann Neurol 2010, 67:A13-A15.
25. Reekers JA, Lee MJ, Belli AM, Barkhof F. Cardiovascular and Interventional Radiological Society of Europe commentary on the treatment of chronic cerebrospinal venous insufficiency. Cardiovasc Intervent Radiol 2011, 34:1-2.
26. Dawson JW. The history of disseminated sclerosis. Trans R Soc Edin 1916, 108:397-399.
27. Adams CW. Perivascular iron deposition and other vascular damage in multiple sclerosis. J Neurol Neurosurg Psychiatry 1988, 51:260-265. 10.1136/jnnp.51.2.260, 1031540, 3346691.
28. MacKenzie EL, Iwasaki K, Tsuji Y. Intracellular iron transport and storage: from molecular mechanisms to health implications. Antioxid Redox Signal 2008, 10:997-1030. 10.1089/ars.2007.1893, 2932529, 18327971.
29. Papanikolaou G, Pantopoulos K. Iron metabolism and toxicity. Toxicol Appl Pharmacol 2005, 202:199-211. 10.1016/j.taap.2004.06.021, 15629195.
30. Izawa T, Yamate J, Franklin RJ, Kuwamura M. Abnormal iron accumulation is involved in the pathogenesis of the demyelinating dmy rat but not in the hypomyelinating mv rat. Brain Res 2010, 1349:105-114.
31. Chou SM. Acute haemorrhagic leuencephalitis as vasculinomyelopathy. J Neuropathol Exp Neurol 1982, 42:357-365.
32. Forge JK, Pedchenko TV, LeVine SM. Iron deposits in the central nervous system of SJL mice with experimental allergic encephalomyelitis. Life Sci 1998, 63:2271-2284. 10.1016/S0024-3205(98)00512-8, 9870713.
33. Craelius W, Migdal MW, Luessenhop CP, Sugar A, Mihalakis I. Iron deposits surrounding multiple sclerosis plaques. Arch Pathol Lab Med 1982, 106:397-399.
34. Walton JC, Kaufmann JC. Iron deposits and multiple sclerosis. Arch Pathol Lab Med 1984, 108:755-756.
35. Nguyen-Legros J, Bizot J, Bolesse M, Pulicani JP. ["Diaminobenzidine black" as a new histochemical demonstration of exogenous iron (author's transl). Histochemistry 1980, 66:239-244. 10.1007/BF00495737, 7399970.
36. Erb GL, Osterbur DL, LeVine SM. The distribution of iron in the brain: a phylogenetic analysis using iron histochemistry. Brain Res Dev Brain Res 1996, 93:120-128.
37. LeVine SM. Oligodendrocytes and myelin sheaths in normal, quaking and shiverer brains are enriched in iron. J Neurosci Res 1991, 29:413-419. 10.1002/jnr.490290317, 1920537.
38. LeVine SM, Torres MV. Morphological features of degenerating oligodendrocytes in twitcher mice. Brain Res 1992, 587:348-352. 10.1016/0006-8993(92)91018-A, 1525668.
39. Drayer BP, Burger P, Hurwitz B, Dawson D, Cain J, Leong J, Herfkens R, Johnson GA. Magnetic resonance imaging in multiple sclerosis: decreased signal in thalamus and putamen. Ann Neurol 1987, 22:546-550. 10.1002/ana.410220418, 3435073.
40. Bakshi R, Benedict RH, Bermel RA, Caruthers SD, Puli SR, Tjoa CW, Fabiano AJ, Jacobs L. T2 hypointensity in the deep gray matter of patients with multiple sclerosis: a quantitative magnetic resonance imaging study. Arch Neurol 2002, 59:62-68. 10.1001/archneur.59.1.62, 11790232.
41. Bakshi R, Dmochowski J, Shaikh ZA, Jacobs L. Gray matter T2 hypointensity is related to plaques and atrophy in the brains of multiple sclerosis patients. J Neurol Sci 2001, 185:19-26. 10.1016/S0022-510X(01)00477-4, 11266686.
42. Deistung A, Rauscher A, Sedlacik J, Stadler J, Witoszynskyj S, Reichenbach JR. Susceptibility weighted imaging at ultra high magnetic field strengths: theoretical considerations and experimental results. Magn Reson Med 2008, 60:1155-1168. 10.1002/mrm.21754, 18956467.
43. Rauscher A, Sedlacik J, Barth M, Haacke EM, Reichenbach JR. Nonnvasive assessment of vascular architecture and function during modulated blood oxygenation using susceptibility weighted magnetic resonance imaging. Magn Reson Med 2005, 54:87-95. 10.1002/mrm.20520, 15968657.
44. Rauscher A, Sedlacik J, Deistung A, Mentzel HJ, Reichenbach JR. Susceptibility weighted imaging: data acquisition, image reconstruction and clinical applications. Z Med Phys 2006, 16:240-250.
45. Mascalchi M, Filippi M, Floris R, Fonda C, Gasparotti R, Villari N. Diffusion-weighted MR of the brain: methodology and clinical application. Radiol Med 2005, 109:155-197.
46. Juurlink BH. The multiple sclerosis lesion: initiated by a localized hypoperfusion in a central nervous system where mechanisms allowing leukocyte infiltration are readily upregulated?. Med Hypotheses 1998, 51:299-303. 10.1016/S0306-9877(98)90052-4, 9824835.
47. Law M, Saindane AM, Ge Y, Babb JS, Johnson G, Mannon LJ, Herbert J, Grossman RI. Microvascular abnormality in relapsing-remitting multiple sclerosis: perfusion MR imaging findings in normal-appearing white matter. Radiology 2004, 231:645-652. 10.1148/radiol.2313030996, 15163806.
48. Adhya S, Johnson G, Herbert J, Jaggi H, Babb JS, Grossman RI, Inglese M. Pattern of hemodynamic impairment in multiple sclerosis: dynamic susceptibility contrast perfusion MR imaging at 3.0 T. Neuroimage 2006, 33:1029-1035. 10.1016/j.neuroimage.2006.08.008, 1752216, 16996280.
49. Ge Y, Law M, Johnson G, Herbert J, Babb JS, Mannon LJ, Grossman RI. Dynamic susceptibility contrast perfusion MR imaging of multiple sclerosis lesions: characterizing hemodynamic impairment and inflammatory activity. AJNR 2005, 26:1539-1547.
50. Varga AW, Johnson G, Babb JS, Herbert J, Grossman RI, Inglese M. White matter hemodynamic abnormalities precede sub-cortical gray matter changes in multiple sclerosis. J Neurol Sci 2009, 282:28-33. 10.1016/j.jns.2008.12.036, 2737614, 19181347.
51. Aboul-Enein F, Lassmann H. Mitochondrial damage and histotoxic hypoxia: a pathway of tissue injury in inflammatory brain disease?. Acta Neuropathol 2005, 109:49-55. 10.1007/s00401-004-0954-8, 15645261.
52. Jackson JR, Seed MP, Kircher CH, Willoughby DA, Winkler JD. The codependence of angiogenesis and chronic inflammation. FASEB J 1997, 11:457-465.
53. Melillo G. Hypoxia: jump-starting inflammation. Blood 2011, 117:2561-2562. 10.1182/blood-2010-12-324913, 21372159.
54. Argaw AT, Gurfein BT, Zhang Y, Zameer A, John GR. VEGF-mediated disruption of endothelial CLN-5 promotes blood-brain barrier breakdown. Proc Natl Acad Sci USA 2009, 106:1977-1982. 10.1073/pnas.0808698106, 2644149, 19174516.
55. Cho ML, Jung YO, Moon YM, Min SY, Yoon CH, Lee SH, Park SH, Cho CS, Jue DM, Kim HY. Interleukin-18 induces the production of vascular endothelial growth factor (VEGF) in rheumatoid arthritis synovial fibroblasts via AP-1-dependent pathways. Immunol Lett 2006, 103:159-166. 10.1016/j.imlet.2005.10.020, 16368150.
56. Heil M, Clauss M, Suzuki K, Buschmann IR, Willuweit A, Fischer S, Schaper W. Vascular endothelial growth factor (VEGF) stimulates monocyte migration through endothelial monolayers via increased integrin expression. Eur J Cell Biol 2000, 79:850-857. 10.1078/0171-9335-00113, 11139149.
57. Machnik A, Neuhofer W, Jantsch J, Dahlmann A, Tammela T, Machura K, Park JK, Beck FX, Muller DN, Derer W, Goss J, Ziomber A, Dietsch P, Wagner H, van RN, Kurtz A, Hilgers KF, Alitalo K, Eckardt KU, Luft FC, Kerjaschki D, Titze J. Macrophages regulate salt-dependent volume and blood pressure by a vascular endothelial growth factor-C-dependent buffering mechanism. Nat Med 2009, 15:545-552. 10.1038/nm.1960, 19412173.
58. Schweighofer B, Testori J, Sturtzel C, Sattler S, Mayer H, Wagner O, Bilban M, Hofer E. The VEGF-induced transcriptional response comprises gene clusters at the crossroad of angiogenesis and inflammation. Thromb Haemost 2009, 102:544-554. 2886966, 19718476.
59. Fukushima K, Miyamoto S, Tsukimori K, Kobayashi H, Seki H, Takeda S, Kensuke E, Ohtani K, Shibuya M, Nakano H. Tumor necrosis factor and vascular endothelial growth factor induce endothelial integrin repertories, regulating endovascular differentiation and apoptosis in a human extravillous trophoblast cell line. Biol Reprod 2005, 73:172-179. 10.1095/biolreprod.104.039479, 15788755.
60. Carvalho JF, Blank M, Shoenfeld Y. Vascular endothelial growth factor (VEGF) in autoimmune diseases. J Clin Immunol 2007, 27:246-256. 10.1007/s10875-007-9083-1, 17340192.
61. Su JJ, Osoegawa M, Matsuoka T, Minohara M, Tanaka M, Ishizu T, Mihara F, Taniwaki T, Kira J. Upregulation of vascular growth factors in multiple sclerosis: correlation with MRI findings. J Neurol Sci 2006, 243:21-30. 10.1016/j.jns.2005.11.006, 16376944.
62. Proescholdt MA, Jacobson S, Tresser N, Oldfield EH, Merrill MJ. Vascular endothelial growth factor is expressed in multiple sclerosis plaques and can induce inflammatory lesions in experimental allergic encephalomyelitis rats. J Neuropathol Exp Neurol 2002, 61:914-925.
63. Kirk SL, Karlik SJ. VEGF and vascular changes in chronic neuroinflammation. J Autoimmun 2003, 21:353-363. 10.1016/S0896-8411(03)00139-2, 14624758.
64. Roscoe WA, Welsh ME, Carter DE, Karlik SJ. VEGF and angiogenesis in acute and chronic MOG (35-55) peptide induced EAE. J Neuroimmunol 2009, 209:6-15. 10.1016/j.jneuroim.2009.01.009, 19233483.
65. Sasaki M, Lankford KL, Brown RJ, Ruddle NH, Kocsis JD. Focal experimental autoimmune encephalomyelitis in the Lewis rat induced by immunization with myelin oligodendrocyte glycoprotein and intraspinal injection of vascular endothelial growth factor. Glia 2010, 58:1523-1531. 10.1002/glia.21026, 20645414.
66. Seabrook TJ, Littlewood-Evans A, Brinkmann V, Pollinger B, Schnell C, Hiestand PC. Angiogenesis is present in experimental autoimmune encephalomyelitis and pro-angiogenic factors are increased in multiple sclerosis lesions. J Neuroinflammation 2010, 7:95-105. 10.1186/1742-2094-7-95, 3022818, 21176212.
67. Tham E, Gielen AW, Khademi M, Martin C, Piehl F. Decreased expression of VEGF-A in rat experimental autoimmune encephalomyelitis and in cerebrospinal fluid mononuclear cells from patients with multiple sclerosis. Scand J Immunol 2006, 64:609-622. 10.1111/j.1365-3083.2006.01851.x, 17083617.
68. Kazazi-Hyseni F, Beijnen JH, Schellens JH. Bevacizumab. Oncologist 2010, 15:819-825. 10.1634/theoncologist.2009-0317, 20688807.
69. Halin C, Fahrngruber H, Meingassner JG, Bold G, Littlewood-Evans A, Stuetz A, Detmar M. Inhibition of chronic and acute skin inflammation by treatment with a vascular endothelial growth factor receptor tyrosine kinase inhibitor. Am J Pathol 2008, 173:265-277. 10.2353/ajpath.2008.071074, 2438303, 18535184.
70. Schonthaler HB, Huggenberger R, Wculek SK, Detmar M, Wagner EF. Systemic anti-VEGF treatment strongly reduces skin inflammation in a mouse model of psoriasis. Proc Natl Acad Sci USA 2009, 106:21264-21269. 10.1073/pnas.0907550106, 2795522, 19995970.
71. Miotla J, Maciewicz R, Kendrew J, Feldmann M, Paleolog E. Treatment with soluble VEGF receptor reduces disease severity in murine collagen-induced arthritis. Lab Invest 2000, 80:1195-1205. 10.1038/labinvest.3780127, 10950110.
72. Gimbrone MA, Alexander RW. Angiotensin II stimulation of prostaglandin production in cultured human vascular endothelium. Science 1975, 189:219-220. 10.1126/science.1138377, 1138377.
73. Schlondorff D, Perez J, Satriano JA. Differential stimulation of PGE2 synthesis in mesangial cells by angiotensin and A23187. Am J Physiol 1985, 248:C119-C126.
74. Williams B, Baker AQ, Gallacher B, Lodwick D. Angiotensin II increases vascular permeability factor gene expression by human vascular smooth muscle cells. Hypertension 1995, 25:913-917.
75. Pastore L, Tessitore A, Martinotti S, Toniato E, Alesse E, Bravi MC, Ferri C, Desideri G, Gulino A, Santucci A. Angiotensin II stimulates intercellular adhesion molecule-1 (ICAM-1) expression by human vascular endothelial cells and increases soluble ICAM-1 release in vivo. Circulation 1999, 100:1646-1652.
76. Tayeh MA, Scicli AG. Angiotensin II and bradykinin regulate the expression of P-selectin on the surface of endothelial cells in culture. Proc Assoc Am Physicians 1998, 110:412-421.
77. Chen XL, Tummala PE, Olbrych MT, Alexander RW, Medford RM. Angiotensin II induces monocyte chemoattractant protein-1 gene expression in rat vascular smooth muscle cells. Circ Res 1998, 83:952-959.
78. Ruiz-Ortega M, Bustos C, Hernandez-Presa MA, Lorenzo O, Plaza JJ, Egido J. Angiotensin II participates in mononuclear cell recruitment in experimental immune complex nephritis through nuclear factor-kappa B activation and monocyte chemoattractant protein-1 synthesis. J Immunol 1998, 161:430-439.
79. Wolf G, Ziyadeh FN, Thaiss F, Tomaszewski J, Caron RJ, Wenzel U, Zahner G, Helmchen U, Stahl RA. Angiotensin II stimulates expression of the chemokine RANTES in rat glomerular endothelial cells. Role of the angiotensin type 2 receptor. J Clin Invest 1997, 100:1047-1058. 10.1172/JCI119615, 508279, 9276721.
80. Gomez RA, Norling LL, Wilfong N, Isakson P, Lynch KR, Hock R, Quesenberry P. Leukocytes synthesize angiotensinogen. Hypertension 1993, 21:470-475.
81. Jurewicz M, McDermott DH, Sechler JM, Tinckam K, Takakura A, Carpenter CB, Milford E, Abdi R. Human T and natural killer cells possess a functional renin-angiotensin system: further mechanisms of angiotensin II-induced inflammation. J Am Soc Nephrol 2007, 18:1093-1102. 10.1681/ASN.2006070707, 17329576.
82. Guzik TJ, Hoch NE, Brown KA, McCann LA, Rahman A, Dikalov S, Goronzy J, Weyand C, Harrison DG. Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. J Exp Med 2007, 204:2449-2460. 10.1084/jem.20070657, 2118469, 17875676.
83. Pool JL. The role of angiotensin II in hypertension and end-organ damage. Int J Clin Pract Suppl 2000, 4-8.
84. Matsushita T, Isobe N, Kawajiri M, Mogi M, Tsukuda K, Horiuchi M, Ohyagi Y, Kira J. CSF angiotensin II and angiotensin-converting enzyme levels in anti-aquaporin-4 autoimmunity. J Neurol Sci 2010, 295:41-45. 10.1016/j.jns.2010.05.014, 20541774.
85. Constantinescu CS, Goodman DB, Grossman RI, Mannon LJ, Cohen JA. Serum angiotensin-converting enzyme in multiple sclerosis. Arch Neurol 1997, 54:1012-1015.
86. Platten M, Youssef S, Hur EM, Ho PP, Han MH, Lanz TV, Phillips LK, Goldstein MJ, Bhat R, Raine CS, Sobel RA, Steinman L. Blocking angiotensin-converting enzyme induces potent regulatory T cells and modulates TH1- and TH17-mediated autoimmunity. Proc Natl Acad Sci USA 2009, 106:14948-14953. 10.1073/pnas.0903958106, 2736463, 19706421.
87. Stegbauer J, Lee DH, Seubert S, Ellrichmann G, Manzel A, Kvakan H, Muller DN, Gaupp S, Rump LC, Gold R, Linker RA. Role of the renin-angiotensin system in autoimmune inflammation of the central nervous system. Proc Natl Acad Sci USA 2009, 106:14942-14947. 10.1073/pnas.0903602106, 2736426, 19706425.